Kintara Therapeutics Inc [NASDAQ: KTRA] closed the trading session at $0.11. The company report on December 7, 2023 at 9:00 AM that Kintara Therapeutics Announces Review of Strategic Alternatives.
– Ladenburg Thalmann Hired as Financial advisor -.
Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value.
The stocks have a year to date performance of -32.55 percent and weekly performance of -20.99 percent. The stock has been moved at -97.24 percent over the last six months. The stock has performed -21.10 percent around the most recent 30 days and changed -73.40 percent over the most recent 3-months.
If compared to the average trading volume of 6.51M shares, KTRA reached to a volume of 3220087 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Kintara Therapeutics Inc [KTRA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for KTRA shares is $14.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on KTRA stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
KTRA stock trade performance evaluation
Kintara Therapeutics Inc [KTRA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -20.99. With this latest performance, KTRA shares dropped by -21.10% in over the last four-week period, additionally sinking by -97.24% over the last 6 months – not to mention a drop of -98.38% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for KTRA stock in for the last two-week period is set at 32.70, with the RSI for the last a single of trading hit 36.41, and the three-weeks RSI is set at 29.89 for Kintara Therapeutics Inc [KTRA]. The present Moving Average for the last 50 days of trading for this stock 0.1856, while it was recorded at 0.1226 for the last single week of trading, and 2.5913 for the last 200 days.
Kintara Therapeutics Inc [KTRA]: An insightful look at the core fundamentals
Kintara Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.23 and a Current Ratio set at 0.23.
Earnings per share (EPS) analysis for Kintara Therapeutics Inc [KTRA] stock
With the latest financial reports released by the company, Kintara Therapeutics Inc posted -3.5/share EPS, while the average EPS was predicted by analysts to be reported at 0/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for KTRA.
Kintara Therapeutics Inc [KTRA]: Institutional Ownership
The top three institutional holders of KTRA stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in KTRA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in KTRA stock with ownership which is approximately 5.8325%.